# HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

> **NCT05905939** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 774 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05905939
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-31
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-03-29
- **Target enrollment:** 774 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905939, "HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05905939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*